Pfizer’s 1,300 acre campus in Kalamazoo is a vertically-integrated powerhouse

Pfizer’s 1,300 acre campus in Kalamazoo is a vertically-integrated powerhouse that makes API, sterile injectables, liquids/semisolids and surgical devices for 120 countries worldwide. Already the largest site in Pfizer’s global network, a new $1.3 billion investment is underway with a new multi-phased Modular Aseptic Processing (MAP) program in development.

🔷 Campus Scale & Complexity: The 1,300 acres campus, with over >3,300 workers outputs ≈1,200 tones of API and worth over $140 million in finished-medicine units every year.
‍
🔷 MAP Investment: Phase 1 – the $465 million investment will deliver a 420,000 ft², multi-storey aseptic block which is expected to come into operation this year.
‍
🔷 Phase 2 – A $750 million investment adds a modular mRNA-ready lines and another 300 roles.
‍
🔷 Further Upgrades: US $120million API line investment will result in the localisation of PAXLOVID™ , creating 250 high-skill jobs.

PlantQuest Insight: At 1,300 acres and three distinct production streams producing both 1,200 tones of API and 140 million finished units each year, Kalamazoo is effectively a dozen factories stitched together. Dropping a 420 k ft² aseptic skyscraper into that live maze—then doubling it—demands centimetre-perfect digital twins of every pipe rack, cable tray and material-flow corridor. When the scale and product mix are this complex, asset-visibility isn’t a luxury; it’s the only way to keep tie-ins clash-free, compress CQV timelines, and bring new mRNA lines online right-first-time.